ABSTRACT
Objective To evaluate the curative effect of dydrogesterone and luteosterone in the treatment of threatened abortion.Methods PubMed,Chinese CNKI,Wanfang database were searched by computer.The randomized controlled trials (RCT) of dydrogesterone and luteosterone in the treatment of threatened abortion(RCT) were collected.Retrieval time was January 2011-March 2016.According to the inclusion and exclusion criteria,the two reviewers independently screened the literature,extracted data and evaluated the quality of themethod,the Rev Man 5.3 software was used for Meta analysis.Results In the final 8 RCT,a total of 1 438 patients were selected.Meta analysis showed:676 cases of 719 patients had clinically effective in the dydrogesterone group,and 605 cases of 719 patients had clinically effective in the luteosterone group(OR =2.94,95％ CI =2.04 ～ 4.24).The clinical effect of the dydrogesterone group was significantly higher than that of the luteosterone group(P ＜ 0.01).The funnel plot was basically symmetrical,and the publication bias was small.The occurrence incidence rate of adverse reactions of the dydrogesterone group was lower than that of the luteosterone group (OR =0.57,95％ CI =0.36 ～ 0.89,P =0.01).The backache relief time of the dydrogesterone group was significantly lower than that of the luteosterone group(MD =-4.96,95％CI =-5.18 ～-4.73,P ＜ 0.01).The relief time of abdominal pain of the dydrogesterone group was significantly lower than that of the luteosterone group (M D =-0.85,95 ％ CI =-1.23 ～-0.46,P ＜ 0.01).The hemostasis time of the dydrogesterone group was significantly lower than that of the luteosterone group (MD =-2.87,95％ CI =-3.52 ～-2.22,P ＜ 0.01).Conclusion Compared with the oral luteosterone,dydrogesterone in the treatment of threatened abortion has higher effective rate,less adverse reactions,and the relief time of backache and abdominal pain,hemostasis time is shorter,so dydrogesterone for threatened abortion is obviously better than luteosterone capsules,and it is worthy of clinical reference.